These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39015644)

  • 21. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
    Fan B; Mellinghoff IK; Wen PY; Lowery MA; Goyal L; Tap WD; Pandya SS; Manyak E; Jiang L; Liu G; Nimkar T; Gliser C; Prahl Judge M; Agresta S; Yang H; Dai D
    Invest New Drugs; 2020 Apr; 38(2):433-444. PubMed ID: 31028664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IDH inhibitors in advanced cholangiocarcinoma: Another arrow in the quiver?
    Rizzo A; Ricci AD; Brandi G
    Cancer Treat Res Commun; 2021; 27():100356. PubMed ID: 33799004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ivosidenib and Azacitidine in
    Montesinos P; Recher C; Vives S; Zarzycka E; Wang J; Bertani G; Heuser M; Calado RT; Schuh AC; Yeh SP; Daigle SR; Hui J; Pandya SS; Gianolio DA; de Botton S; Döhner H
    N Engl J Med; 2022 Apr; 386(16):1519-1531. PubMed ID: 35443108
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Secondary IDH1 resistance mutations and oncogenic IDH2 mutations cause acquired resistance to ivosidenib in cholangiocarcinoma.
    Cleary JM; Rouaisnel B; Daina A; Raghavan S; Roller LA; Huffman BM; Singh H; Wen PY; Bardeesy N; Zoete V; Wolpin BM; Losman JA
    NPJ Precis Oncol; 2022 Sep; 6(1):61. PubMed ID: 36056177
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ivosidenib Boosts OS in Cholangiocarcinoma.
    Cancer Discov; 2021 Dec; 11(12):2953-2954. PubMed ID: 34635569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia: a registry study.
    Sun M; Yin Q; Liang Y; Chang C; Zheng J; Li J; Ji C; Qiu H; Li J; Gong Y; Luo S; Zhang Y; Chen R; Shen Z; Yue Z; Wang S; Shi Q; Yang J; Jin J; Wang J
    Blood Sci; 2024 Jul; 6(3):e00196. PubMed ID: 38911469
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multicenter Phase I Trial of Ivosidenib as Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplantation for IDH1-Mutated Acute Myeloid Leukemia.
    Fathi AT; Kim HT; Soiffer RJ; Levis MJ; Li S; Kim AS; DeFilipp Z; El-Jawahri A; McAfee SL; Brunner AM; Amrein PC; Mims AS; Knight LW; Kelley D; Bottoms AS; Perry LH; Wahl JL; Brock J; Breton E; Marchione DM; Ho VT; Chen YB
    Clin Cancer Res; 2023 Jun; 29(11):2034-2042. PubMed ID: 37014667
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical pharmacokinetics and pharmacodynamics of ivosidenib in patients with advanced hematologic malignancies with an IDH1 mutation.
    Fan B; Dai D; DiNardo CD; Stein E; de Botton S; Attar EC; Liu H; Liu G; Lemieux I; Agresta SV; Yang H
    Cancer Chemother Pharmacol; 2020 May; 85(5):959-968. PubMed ID: 32296873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular and morphological changes induced by ivosidenib correlate with efficacy in mutant-
    Aguado-Fraile E; Tassinari A; Ishii Y; Sigel C; Lowery MA; Goyal L; Gliser C; Jiang L; Pandya SS; Wu B; Bardeesy N; Choe S; Deshpande V
    Future Oncol; 2021 Jun; 17(16):2057-2074. PubMed ID: 33709779
    [No Abstract]   [Full Text] [Related]  

  • 30. Spectrum of Findings Seen in Patients With
    Kierans AS; Lutfi A; Afghan MK; Khan S; Javaid S; Currie BM; Rocca J; Samstein B; Golden E; Popa E; Hissong E; Kasi PM
    Int J Surg Pathol; 2024 Sep; ():10668969241271397. PubMed ID: 39314068
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Ivosidenib: an investigational drug for the treatment of biliary tract cancers.
    Angelakas A; Lamarca A; Hubner RA; McNamara MG; Valle JW
    Expert Opin Investig Drugs; 2021 Apr; 30(4):301-307. PubMed ID: 33683991
    [No Abstract]   [Full Text] [Related]  

  • 32. Platinum sensitivity in patients with IDH1/2 mutated vs wild-type intrahepatic cholangiocarcinoma: A propensity score-based study.
    Niger M; Nichetti F; Casadei-Gardini A; Rizzato MD; Pircher C; Bini M; Franza A; Rimini M; Burgio V; Sposetti C; Fornaro L; Rapposelli IG; D'Amico FE; Aprile G; Vivaldi C; Frassineti GL; Milione M; Leoncini G; Cappetta A; Vasile E; Fassan M; Morano F; Perrone F; Tamborini E; Pruneri G; Lonardi S; Mazzaferro V; Pietrantonio F; Di Bartolomeo M; de Braud F
    Int J Cancer; 2022 Oct; 151(8):1310-1320. PubMed ID: 35723131
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ivosidenib in Isocitrate Dehydrogenase 1
    Mellinghoff IK; Ellingson BM; Touat M; Maher E; De La Fuente MI; Holdhoff M; Cote GM; Burris H; Janku F; Young RJ; Huang R; Jiang L; Choe S; Fan B; Yen K; Lu M; Bowden C; Steelman L; Pandya SS; Cloughesy TF; Wen PY
    J Clin Oncol; 2020 Oct; 38(29):3398-3406. PubMed ID: 32530764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An evaluation of ivosidenib for the treatment of
    Tella SH; Mahipal A
    Expert Opin Pharmacother; 2022 Dec; 23(17):1879-1885. PubMed ID: 36257911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive Immunogenomic Profiling of
    Makawita S; Lee S; Kong E; Kwong LN; Abouelfetouh Z; Danner De Armas A; Xiao L; Murugesan K; Danziger N; Pavlick D; Korkut A; Ross JS; Javle M
    JCO Precis Oncol; 2024 Mar; 8():e2300544. PubMed ID: 38547421
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Cercek A; Boerner T; Tan BR; Chou JF; Gönen M; Boucher TM; Hauser HF; Do RKG; Lowery MA; Harding JJ; Varghese AM; Reidy-Lagunes D; Saltz L; Schultz N; Kingham TP; D'Angelica MI; DeMatteo RP; Drebin JA; Allen PJ; Balachandran VP; Lim KH; Sanchez-Vega F; Vachharajani N; Majella Doyle MB; Fields RC; Hawkins WG; Strasberg SM; Chapman WC; Diaz LA; Kemeny NE; Jarnagin WR
    JAMA Oncol; 2020 Jan; 6(1):60-67. PubMed ID: 31670750
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers.
    Popovici-Muller J; Lemieux RM; Artin E; Saunders JO; Salituro FG; Travins J; Cianchetta G; Cai Z; Zhou D; Cui D; Chen P; Straley K; Tobin E; Wang F; David MD; Penard-Lacronique V; Quivoron C; Saada V; de Botton S; Gross S; Dang L; Yang H; Utley L; Chen Y; Kim H; Jin S; Gu Z; Yao G; Luo Z; Lv X; Fang C; Yan L; Olaharski A; Silverman L; Biller S; Su SM; Yen K
    ACS Med Chem Lett; 2018 Apr; 9(4):300-305. PubMed ID: 29670690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.
    Jiang X; Wada R; Poland B; Kleijn HJ; Fan B; Liu G; Liu H; Kapsalis S; Yang H; Le K
    Clin Transl Sci; 2021 May; 14(3):942-953. PubMed ID: 33493392
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma.
    Yu Q; Ungchusri E; Pillai A; Liao CY; Baker T; Fung J; DiSabato D; Zhang M; Liao C; Van Ha T; Ahmed O
    Eur Radiol; 2024 Apr; 34(4):2374-2383. PubMed ID: 37812295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
    DiNardo CD; Stein AS; Stein EM; Fathi AT; Frankfurt O; Schuh AC; Döhner H; Martinelli G; Patel PA; Raffoux E; Tan P; Zeidan AM; de Botton S; Kantarjian HM; Stone RM; Frattini MG; Lersch F; Gong J; Gianolio DA; Zhang V; Franovic A; Fan B; Goldwasser M; Daigle S; Choe S; Wu B; Winkler T; Vyas P
    J Clin Oncol; 2021 Jan; 39(1):57-65. PubMed ID: 33119479
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.